Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance

被引:75
作者
Guo, Tianhua [1 ]
Hajdu, Mihai [1 ]
Agaram, Narasimhan P. [1 ]
Shinoda, Hiroko [1 ]
Veach, Darren [4 ]
Clarkson, Bayard D. [4 ]
Maki, Robert G. [2 ]
Singer, Samuel [3 ]
DeMatteo, Ronald P. [3 ]
Besmer, Peter [5 ]
Antonescu, Cristina R. [1 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[4] Sloan Kettering Inst, Mol Pharmacol & Chem Program, New York, NY USA
[5] Sloan Kettering Inst, Dev Biol Program, New York, NY USA
关键词
IMATINIB MESYLATE; KINASE INHIBITOR; KIT MUTATIONS; MUTANTS; ACTIVATION; EFFICACY; GENE;
D O I
10.1158/1078-0432.CCR-09-1315
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Although tyrosine kinase inhibitors have improved survival in advanced gastrointestinal stromal tumor (GIST), complete response is rare and most patients eventually fail the first-line treatment with imatinib. Sunitinib malate is the only approved second-line therapy for patients with imatinib-resistant or imatinib-intolerant GIST. The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KITAY502-3ins exon 9 mutation being the most sensitive. Experimental Design: As sunitinib resistance is now emerging, our goal was to investigate mechanisms of progression and to test the efficacy of novel tyrosine kinase inhibitor on these resistant mutants in vitro. N-ethyl-N-nitrosourea mutagenesis of Ba/F3 cells expressing the KITAY502-3ins mutant was used to investigate novel patterns of resistant mutations evolving in the presence of sunitinib. Results: Tumors from patients who developed sunitinib resistance after at least 1 year of radiographic response were analyzed, showing similar findings of a primary KITAY502-3ins mutation and a secondary mutation in the KIT activation loop. Ba/F3 cells expressing these sunitinib-resistant double mutants showed sensitivity to both dasatinib and nilotinib. Conclusions: Sunitinib resistance in GIST shares similar pathogenetic mechanisms identified in imatinib failure, with acquisition of secondary mutations in the activation domain after an extended initial response to the drug. Moreover, in vitro mutagenesis with or without N-ethyl-N-nitrosourea of Ba/F3 cells expressing KITAY502-3ins showed acquisition of secondary mutations restricted to the second kinase domain of KIT. In contrast, in vitro resistance to imatinib produces a broader spectrum of secondary mutations including mutations in both KIT kinase domains. (Clin Cancer Res 2009;15(22):6862-70)
引用
收藏
页码:6862 / 6870
页数:9
相关论文
共 24 条
[1]   Molecular characterization of pediatric gastrointestinal stromal tumors [J].
Agaram, Narasimhan P. ;
Laquaglia, Michael P. ;
Ustun, Berrin ;
Guo, Tianhua ;
Wong, Grace C. ;
Socci, Nicholas D. ;
Maki, Robert G. ;
DeMatteo, Ronald P. ;
Besmer, Peter ;
Antonescu, Cristina R. .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3204-3215
[2]  
Antonescu CR, 2003, CLIN CANCER RES, V9, P3329
[3]   Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].
Antonescu, CR ;
Besmer, P ;
Guo, TH ;
Arkun, K ;
Hom, G ;
Koryotowski, B ;
Leversha, MA ;
Jeffrey, PD ;
Desantis, D ;
Singer, S ;
Brennan, MF ;
Maki, RG ;
DeMatteo, RP .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190
[4]   Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].
Blanke, Charles D. ;
Demetri, George D. ;
von Mehren, Margaret ;
Heinrich, Michael C. ;
Eisenberg, Burton ;
Fletcher, Jonathan A. ;
Corless, Christopher L. ;
Fletcher, Christopher D. M. ;
Roberts, Peter J. ;
Heinz, Daniela ;
Wehre, Elisabeth ;
Nikolova, Zariana ;
Joensuu, Heikki .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625
[5]   Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].
Bradeen, Heather A. ;
Eide, Christopher A. ;
O'Hare, Thomas ;
Johnson, Kara J. ;
Willis, Stephanie G. ;
Lee, Francis Y. ;
Druker, Brian J. ;
Deininger, Michael W. .
BLOOD, 2006, 108 (07) :2332-2338
[6]   Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants [J].
Debiec-Rychter, M ;
Cools, J ;
Dumez, H ;
Sciot, R ;
Stul, M ;
Mentens, N ;
Vranckx, H ;
Wasag, B ;
Prenen, H ;
Roesel, J ;
Hagemeijer, A ;
Van Oosterom, A ;
Marynen, P .
GASTROENTEROLOGY, 2005, 128 (02) :270-279
[7]   KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].
Debiec-Rychter, Maria ;
Sciot, Raf ;
Le Cesne, Axel ;
Schlemmer, Marcus ;
Hohenberger, Peter ;
van Oosterom, Allan T. ;
Blay, Jean-Yves ;
Leyvraz, Serge ;
Stul, Michel ;
Casali, Paolo G. ;
Zalcberg, John ;
Verweij, Jaap ;
Van Glabbeke, Martine ;
Hagemeijer, Anne ;
Judson, Ian .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103
[8]   Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].
Demetri, George D. ;
van Oosterom, Allan T. ;
Garrett, Christopher R. ;
Blackstein, Martin E. ;
Shah, Manisha H. ;
Verweij, Jaap ;
McArthur, Grant ;
Judson, Ian R. ;
Heinrich, Michael C. ;
Morgan, Jeffrey A. ;
Desai, Jayesh ;
D Fletcher, Christopher ;
George, Suzanne ;
Bello, Carlo L. ;
Huang, Xin ;
Baum, Charles M. ;
Casali, Paolo G. .
LANCET, 2006, 368 (9544) :1329-1338
[9]   Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) [J].
Duensing, A ;
Medeiros, F ;
McConarty, B ;
Joseph, NE ;
Panigrahy, D ;
Singer, S ;
Fletcher, CDM ;
Demetri, GD ;
Fletcher, JA .
ONCOGENE, 2004, 23 (22) :3999-4006
[10]   KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients [J].
Gajiwala, Ketan S. ;
Wu, Joe C. ;
Christensen, James ;
Deshmukh, Gayatri D. ;
Diehl, Wade ;
DiNitto, Jonathan P. ;
English, Jessie M. ;
Greig, Michael J. ;
He, You-Ai ;
Jacques, Suzanne L. ;
Lunney, Elizabeth A. ;
McTigue, Michele ;
Molina, David ;
Quenzer, Terri ;
Wells, Peter A. ;
Yu, Xiu ;
Zhang, Yan ;
Zou, Aihua ;
Emmett, Mark R. ;
Marshall, Alan G. ;
Zhang, Hui-Min ;
Demetri, George D. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (05) :1542-1547